Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4

Diabetes Obes Metab. 2025 Feb;27(2):1010-1013. doi: 10.1111/dom.16079. Epub 2024 Nov 20.

Authors

Vikas S Sridhar^{1

2

3}, Michael J Davies⁴, Phillip Banks⁴, Manon Girard⁴, Amy K Carroll⁴, David Z I Cherney^{1

2

3}

Affiliations

¹ Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
² Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
³ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.

No abstract available

Keywords: SGLT2 inhibitors; anaemia; chronic kidney disease; type 2 diabetes.

Publication types

Letter